BioFocus Announces Agreement with ChanTest
News Feb 07, 2013
BioFocus and ChanTest have announced an agreement which will enable BioFocus to offer ChanTest’s extensive cell line library (> 200 products) and Channel Panel™ profiling services.
This expands BioFocus’ offering in the fields of ion channel, GPCR and transporter targets for drug discovery.
“With access to ChanTest’s cell line collection and ion channel profiling, we have further augmented our suite of integrated drug discovery services, designed to deliver efficiency and success to our partners,” said Kate Hilyard, VP Biological Sciences, BioFocus.
Chris Mathes, Ph.D., M.B.A, Chief Commercial Officer, ChanTest, commented, “This collaboration with BioFocus fits well with ChanTest’s integrated CRO strategy, and we are delighted to partner with a company with such a strong reputation.”
U.S. Study of Dapivirine Ring in Lactating Women Finds Little Drug Gets Into Breast MilkNews
The antiretroviral drug dapivirine that is released from an experimental vaginal ring to protect against HIV is absorbed in very low concentrations into breastmilk.READ MORE
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018